An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs SB 01 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors SynCore Biotechnology
- 18 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 18 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 18 Oct 2017 Status changed from recruiting to discontinued.